Protocol Ledger

NCT06463665 · Phase II · RECRUITING

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

Interventional Phase II clinical trial protocol NCT06463665 sponsored by Genelux in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-09-26 Enrollment: 142 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06463665
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)142 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06463665
Protocol FieldVerified Registry Value
NCT IdentifierNCT06463665
Consolidated Lead SponsorGenelux
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment142 participants (ESTIMATED)
Registered Start Date2024-09-26
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI